FAP is an inherited, colorectal cancer syndrome characterized by the growth of colorectal polyps. Though the polyps are initially benign, they become malignant in nearly all cases in the absence of colectomy, according to Marina.
The company's vice president of corporate development said that Marina is "committed" to signing two partnerships before year end, but indicated that it may miss this goal if the terms of the deals aren't right.
CEQ508 is based on Cequent Pharmaceuticals' so-called transkingdom RNAi technology, and is designed to inhibit the oncogene beta-catenin, which is expected to prevent new polyp formation associated with the disease.
The drug is designed to treat advanced familial adenomatous polyposis by inhibiting the oncogene beta-catenin, which is expected to prevent the formation of polyps characterizing the disease and possibly slow the progression to malignancy of existing ones.
The company also remains on track with its more advanced familial adenomatous polyposis drug and plans to file within the next two weeks an investigational new drug application to begin testing the therapy in humans.